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Cells transcribe a broad spectrum of RNA molecules, ranging from
long protein-coding mRNAs to short noncoding transcripts that fre-
quently overlap or are interleaved on either strand. A large proportionVeterinary Etiological Biology,
, Lanzhou Veterinary Research
ou, Gansu 730046, China.
gyongguang@caas.cn
. This is an open access article underof the eukaryotic genome that is transcribed thus produces a broad
array of RNA molecules of differing size, abundance, and protein-
coding ability [1]. The functions of only a small number of non-
protein-coding transcripts have been experimentally described, but
disease-associated mutations have rarely been identiﬁed in other than
protein-coding genes. Wang et al. [2] proposed, following the annota-
tion of cDNA sequences, that much of the mouse genome's repertoire
of non-protein-coding might be inconsequential transcriptional noise.
The non-coding RNA (ncRNA) transcribed by eukaryotic cells can be
divided into two groups, regulatory and housekeeping RNAs depending
on their expression pattern and function. Housekeeping RNAs includethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
151Y. Ding et al. / Genomics 107 (2016) 150–154tRNA and rRNA. Regulatory RNAs are characterized by sequence length
either as small regulatory RNA (b100 nucleotides) or as long noncoding
(lnc)RNA (N100 nucleotides).
LncRNAs do not encode any proteins, have a polyA tail, promoter se-
quence, are spliced, and are speciﬁcally expressed in different tissues
and developmental processes. The functional conceptwas ﬁrst reported
by Japanese scientists in 2002 [3]. Three types of lncRNA have been rec-
ognized. These include at least 5000 large intervening ncRNAs
(lincRNAs) present in intergenic regions of the genome, natural anti-
sense transcripts (NATs) and intronic lncRNAs [4]. Recent publications
estimate that the three lncRNAs include approximately 20,000 tran-
scripts [5]. A report by Rinn et al. in 2007 [6] describing the function
of HOTAIR (HOX transcript antisense RNA), a 2.2 KB lncRNA stimulated
additional research on the physiological and pathological functions of
lncRNAs. The functions and mechanisms of lncRNA, which have been
the subject of recent reviews [7,8], are still in the initial stage.
To date, evidence from in vitro studies of over 200 lncRNAs [4] sug-
gests that lncRNAmayhave clinical importance asmolecularmarkers to
predict the prognosis of cancer patients [4,9,10]. Several lncRNA mole-
cules have been associated with prognosis in liver cancer resection,
liver transplantation [11–13], and after surgical treatment of tumors
[14,15]. Questions remain concerning the special relationship of
lncRNAs and viruses. We review here what is currently known of ex-
pression and regulation of lncRNAs that interact with viruses to foster
continuing research on both lncRNAs and viruses.
2. LncRNA expression
Recent studies of lncRNA transcription and function have compared
it tomicro (mi)RNA;most lncRNAs, such as lincRNA, can be divided into
independent transcription units by RNA polymerase. Some studies [16,
17] have conﬁrmed that the transcription of lncRNAs is similar to coding
genes, including the acetylation of histones and DNAmethylation. Tran-
scription assays have shown that some lncRNAs can promote the ex-
pression of neighboring genes [18]. Following DNA damage, p53 can
induce transcription of lncRNA-p21, which then represses the expres-
sion of genes transcriptionally regulated by p53 [19]. These ﬁndings
suggest that lncRNAs can participate in the regulation of gene expres-
sion and function in eukaryotic cells.
Other ways of producing lncRNAs are derived from shear though
some transcripts are lacking of the initiation codon or other that have
no original translation cannot form coding function. For example,
siRNA complementary with coding RNA can mediate mRNA degrada-
tion [20]. Similar to protein-coding RNAs, many lncRNAs have polyA
tails and a 5′ cap structure, which are the characteristics of RNA poly-
merase II transcripts. They may also have degradation pathways and
the regulation process similar to mRNAs.
3. LncRNA functions
LncRNA is a recently described species of RNA found throughout the
genome, but its functions are poorly understood. In the nucleus, lncRNA
transcription is required for epigenetic modiﬁcation of chromosomal
complexes in either a transcription-initiation dependent or RNA-
independent manner, to regulate expression of overlapping or nearby
genes, as shown by lncRNA Xist [21,22] and known as lncRNA CIS-
activity [23]. Other lncRNAs can remotely regulate gene expression by
binding to and modifying chromatin complexes or by epigenetic modi-
ﬁcation of histone proteins to change gene expression, i.e., lncRNA
trans-activity [24] as shown by lncRNA HOTAIR [25]. A group of
lincRNAs was found to function as enhancers to positively regulate the
expression of nearby protein encoding genes [26]. LncRNAsmayoverlap
with promoter regions, and assist protein coding gene tomaintain tran-
scription, which suggests that this may be a common mechanism of
gene regulation in mammals [27].Cytoplasmic LncRNAs include competing endogenous RNA (ceRNA),
that bind microRNA response elements (MREs), forming an extensive
regulatory “crosstalk” network across the transcriptome. Competition
between ceRNAs andmRNAs for binding toMREs expands the function-
al genetic information and plays an important role in pathological con-
ditions. Brieﬂy, lncRNAs competitively combine with endogenous
miRNA to release the target mRNA accelerate its translation [28,29].
LncRNAs also transactivate Staufen1 (STAU1)-mediated mRNA decay
by duplexing with 3′-UTRs via Alu elements. Previous studies deﬁned
the STAU1 binding site (SBS) within ADP ribosylation factor 1 (ARF1)
mRNA [30]. Other researchers have failed to ﬁnd the structures within
the 3′-UTRs of other SMD targets [31], but found that SBSs can form
by imperfect base-pairing between an Alu element within the 3′-UTR
of an SMD target and another Alu element within a cytoplasmic,
polyadenylated lncRNA. LncRNAs can downregulate a subset of SMD
targets, and different lncRNAs can downregulate the same SMD target.
The ﬁnding that STAU1 binding to mRNAs can be transactivated by
lncRNAs reveals an unexpected strategy used by cells to recruit proteins
tomRNAs andmediate their decay [31]. Another recent study described
a 3.7-kilobase lncRNATINCR that bound STAU1protein to stabilize a tar-
get mRNA required for tissue differentiation [32]. A third cytoplasmic
lncRNA can bind with a coding gene exon overlapping antisense RNA
BACE1-AS to increase the stability of β-secretase-1 (BACE1) and pro-
mote Alzheimer's disease. Recent evidence indicates that a conserved
noncoding antisense transcript for BACE1, is a key enzyme in
Alzheimer's disease pathophysiology. The BACE1-antisense transcript
(BACE1-AS) regulates BACE1mRNA and thus BACE1 protein expression
in vitro and in vivo. BACE1 mRNA expression may thus be controlled by
a regulatory ncRNA that drives the Alzheimer's disease-associated path-
ophysiology [20].
4. Relationship of LncRNAs with viruses
The function, type, quantity and themechanismof lncRNAs have not
yet been deﬁned. Current research indicates that those viruses canmod-
ulate host and/or viral gene expression via lncRNAs that maintain the
virus latency or replication [33]. Some lncRNAs assist virus replication,
escape from cytosolic surveillance, and decrease antiviral immunity. Re-
vealing the relationship between the lncRNAs and viruses would pro-
vide a new perspective of viral disease and may reveal ncRNAs as a
potential targets for new antiviral drugs.
5. The lncRNA and Epstein–Barr virus (EBV)
Epstein–Barr virus-encoded small RNAs (EBERs) include EBER1
(167 nt) and EBER2 (172 nt). LncRNAs that take on a stem–loop struc-
ture by intermolecular base-pairing exist abundantly along with viral
transcripts in cells latently infectedwith EBV [34], and bind to a number
of cellular proteins, including lupus erythematosis-associated antigen
(La) [35], and retinoic acid-inducible gene I (RIG-I) [36]. EBERs are tran-
scribed by cellular RNA Polymerase III (pol III) and are strongly
expressed in EBV-infected cells [34,37].
EBER can induce signaling from the Toll-like receptor 3 (TLR3),
which is a sensor of viral dsRNA and inducer of type I interferon (IFN)
and proinﬂammatory cytokines [37]. Substantial amounts of EBER, the
majority of which was complexed with cellular EBER-binding La pro-
tein, were released from EBV-infected cells. RNA puriﬁed from sera
from EBV patients induced TLR3 signaling in EBV-transformed lympho-
cytes and peripheral mononuclear cells. In addition, dendritic cells
(DCs) exposed to EBER showed a mature phenotype and antigen pre-
sentation capacity. These ﬁndings suggest that EBER is responsible for
immune activation by EBV [38].
A recent report indicated that EBER2 and not EBER1 plays a central
role in B-cell growth transformation even though EBER1 and EBER2
have similar structures [39]. There is additional evidence that the in-
crease of insulin like growth factor (IGF-1) expression can reverse
152 Y. Ding et al. / Genomics 107 (2016) 150–154transcription activation that plays a role in the EBER-induced expression
of IGF-1. EBER is expressed in the EBV-associated malignant tumor, in-
cluding nasopharyngeal carcinoma (NPC). In addition, EBV infection
can confer resistance to various stimuli of apoptosis and contribute to
the maintenance of Burkitt lymphoma. Transfection of EBER gene into
intestine 407 cells, can signiﬁcantly protect against Fas-mediated
phagocytosis [37].
6. LncRNA and Theiler's virus
Theiler's murine encephalomyelitis virus (TMEV), a member of the
Cardiovirus genus in the family Picornaviridae, is a highly cytolytic
virus that produces necrotic death in rodent cells, including neurons
and oligodendrocytes [40]. Tmevpg1, also named NeST and IfngAS1, is
about 173 kb long, is expressed at a low level in the spleen and thymus,
and occasionally in the liver and kidneys, of B10.Smice, but never in the
central nervous system (CNS). Tmevpg1 has a human ortholog,
TMEVPG1, with homologies to the mouse gene only in exon 1 and the
region surrounding it. Tmevpg1 and its human ortholog, TMEVPG1, are
expressed in the immune system and encodewhat appears to be a non-
coding RNA. They are both located in a cluster of cytokine genes that in-
cludes the genes for γ-ITF and one or two IL-10 homologs. Tmevpg1 is
expressed in CNS-inﬁltrating immune cells of resistant B10.S mice inoc-
ulated with Theiler's virus, and Tmevpg1 is down regulated after in vitro
stimulation of murine CD4+ or CD8+ splenocytes. Similar patterns of
TMEVPG1 and IFNG were observed in human NK cells and CD4+ and
CD8+ T lymphocytes. Therefore, Tmevpg1 is a strong candidate gene
for the Tmevp3 locus andmay be involved in the control of Ifng gene ex-
pression. Elucidation of this mechanism may help us to understand the
persistent infection by Theiler's virus [40]. TMEVPG1, was initially iden-
tiﬁed as a lincRNA transcript in the context of Theiler's virus infection,
and mice lacking in TMEVPG1 expression were unable to control intra-
cranial viral infection. Both TMEVPG1 and its mouse ortholog encode
lincRNAs and are positioned near the IFN-g gene (IFNG). In a recent
study, Collier et.al showed that the transcription of both mouse and
human TMEVPG1 genes is Th1-selective and dependent on Stat4 and
T-bet, which are transcription factors that drive the Th1 differentiation
program. Ifng expression was partially restored in Stat42/2 Tbx212/2
cells through coexpression of T-bet and Tmevpg1. The results suggested
that TMEVPG1 could positively regulate gene transcription, and showed
that T-bet guides epigenetic remodeling of Tmevpg1 proximal and dis-
tal enhancers, leading to recruitment of stimulus-inducible transcrip-
tion factors, NF-kB and Ets-1, to the locus. Activities of Tmevpg1-
speciﬁc enhancers and Tmevpg1 transcription are dependent upon
NF-kB [41,42]. An enhancer-like lncRNANeSTwas shown to be required
for all phenotypes conferred by the murine viral susceptibility locus
Tmevp3 which was characterized in SJL/J and B10.S mice and contains
several candidate genes, including NeST. The SJL/J-derived locus confers
increased lncRNA expression, increased interferon-γ expression in acti-
vated CD8+T cells, increased Theiler's virus persistence, and decreased
Salmonella entericapathogenesis. Transgenic expression of NeST lncRNA
alonewas sufﬁcient to confer all phenotypes of the SJL/J locus. NeSTRNA
can be bind to WDR5, a component of the histone H3 lysine 4
methytransferase complex, and to alter histone 3 methylation at the
interferon-γ locus. LncRNA thus regulates epigenetic marking of IFNγ-
encoding chromatin, expression of IFN-γ, and susceptibility to a viral
and a bacterial pathogen [43].
7. LncRNA and adenovirus
Human adenovirus type 5 (Ad 5) encodes two RNA polymerase III
transcripts of approximately 160 nt, virus-associated (VA) RNA I and
VA RNAII [44]. The VA RNAs are highly structured [45] and can adopt
secondary stem–loop structures similar to micro-RNAs [46]. VA RNA I
binds to protein kinase PKR and acts as a competitive inhibitor [47],
thus preventing the dsRNA produced by symmetrical transcription ofthe viral DNA [48] from activating PKR. Two key enzyme systems are in-
volved in Dicer and the RNA-induced silencing complex (RISC). The
mechanism by which adenovirus blocks RNAi involves suppression
resulting from the interference of VARNAI andRNAIIwithDicer activity.
In addition, VA RNA I and RNA II are processed byDicer both in vitro and
during a lytic infection, with short interfering RNAs (siRNAs) are incor-
porated into an active RNA-induced silencing complex, (RISC). The sup-
pression of RNAi by adenovirus provides insight into themechanisms of
RNAi suppression by VA RNA [49]. Another study reported that approx-
imately 80% of an Ago2 endonuclease-containing RISC immunopuriﬁed
from late-infected cells was associated with VA RNA-derived small
RNAs (mivaRNAs). Surprisingly, the mivaRNAs were derived from the
3′ strand of the VA RNAs terminal stems, with the major fraction of VA
RNAII starting at position 138. The small RNAs derived from VA RNAI
were more heterogeneous in size, with the two predominant small
RNAs starting at positions 137 and 138. The results suggested that the
mivaRNAs are important for RISC assembly in late-infected cells and
function as miRNAs, regulating translation of cellular mRNAs [50].8. LncRNA and cytomegaloviruses
Cytomegaloviruses express large amounts of viral miRNAs during
lytic infection, but they only modestly alter cellular miRNA. The most
prominent alteration observed during lytic murine cytomegalovirus
(MCMV) infection is the rapid degradation of cellular miR-27a and
miR-27b mediated by a spliced and highly abundant 1.7 kb MCMV
m169 transcript. miR-27a/b speciﬁcity is mediated by a single miRNA
binding site located in its 39-UTR. The binding site can be retargeted
to other cellular and viral miRNAs by target site replacement, but no
other viral factors have been found essential to this process. It is inter-
esting thatmutant viruses are no longer able to target miR-27a/b, either
because of miRNA target site disruption or target site replacement, indi-
cating that degradation of miR-27a/b is important for efﬁcient MCMV
replication in vivo [51].
Ischemia/reperfusion injury causes endothelial cell dysfunction and
can precipitate apoptosis. Complex I of the mitochondrial respiratory
chain is a target for ischemia/reperfusion injury. A full-length beta2.7
RNA generated from a human immunodeﬁciency virus-1 construct fol-
lowing beta2.7 gene expression in transduced endothelial cells. It was
shown to stabilize Complex I by direct physical interaction in an
in vitromodel of ischemia developed to showwhether stabilizing Com-
plex I in endothelial cells could prevent apoptosis [52].9. Discussion
LncRNAs have numerous molecular functions including modulation
of transcription patterns, regulating protein activity, serving structural
or organizational roles, altering RNA processing events, and serving as
precursors of small RNAs. Understanding how the molecular functions
of lncRNAs affect physiology and development [53], such as the forma-
tion of photoreceptors in the developing retina [54], regulation of cell
survival, and cell cycle progression during mammary gland develop-
ment [55] is a major challenge. The generation of knockout animal
models will provide insights and conﬁrm that lncRNAs are not tran-
scriptional “noise”, but are required for normal development [56].
LncRNAs are misregulated in various diseases, especially cancer [57,
58], and the way in which those transcripts affect tumor initiation or
progression are currently unknown. Perhaps lncRNAs will prove attrac-
tive targets for developing candidate drugs to control or disease.Competing interests
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